Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials

Target Audience

This online educational activity is directed toward rheumatologists, pulmonologists, dermatologists, and specialty nurse practitioners and physician assistants. Additional health care clinicians involved in the management of patients with SSc-ILD will also be invited to participate.

Activity Overview

Interstitial lung disease (ILD) is a frequent and debilitating complication of systemic sclerosis (SSc) with a complex pathophysiology. SSc-ILD is a pulmonary fibrosing disorder characterized by systemic inflammation, progressive scarring of the lungs, and eventual respiratory failure. The presence of ILD in SSc is an important determinant of both disease severity and prognosis. Patients diagnosed with SSc need regular screening for ILD because early detection of progressive lung involvement is critical to starting pharmacologic intervention, which is more beneficial in the early stage of disease.

During this Clinical Consultations™, 2 expert faculty will review risk factors for SSc-ILD and the diagnostic tools used to determine which patients are at risk of disease progression. They will then discuss the latest evidence regarding treatment for SSc-ILD and the importance of a multispecialty approach to managing patients with this disease.

Learning Objectives

Upon completion of this activity, you should be better able to:

Review disease prevalence, pathophysiology, morbidity, and morality of SSc-ILD
Identify key risk factors and diagnostic tests to improve early symptom recognition and prognosis of SSc-ILD
Interpret key data on recently approved and emerging treatment options for SSc-ILD to improve clinical management
Describe best practices for effective communication and coordination between rheumatologists and pulmonologists to optimize patient outcomes